Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (June 2025)
26 slides from Avicanna's investor presentation, June 2025
Slide 1: An International Biopharmaceutical Strategy
Q2 2025 An International Biopharmaceutical Strategy Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments TSX: AVCN OTCQX: AVCNF FS
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations and other applicable secu
Slide 3: Corporate Highlights
0.1 Corporate Highlights An International Medical and Biopharmaceutical Strategy Business Pillars Established Commercial Platform • 4 commercial stage business pillars 1.1 Medical Products Cannabis • 38 commercialized proprietary SKUs • $25.5M revenue, 50%+ GM during 2024 1.2 Medical • Addressing a
Slide 4: The Cannabinoid-Based Medicine Opportunity
0.2 The Cannabinoid-Based Medicine Opportunity The current challenge Medical cannabis use in Canada (symptoms, disease or disorder) Limited separation Lack of education & of Canadian lack basic Canadian Cannabis between Medical and training resources for the knowledge about Cannabis Survey 2024 adul
Slide 5: The separation of adult-use & cannabinoid-based medicine
0.3 The separation of adult-use & cannabinoid-based medicine Adult Use & Recreational Medical Cannabis CB Pharmaceuticals End User Consumers Patients Patients Market Opportunity Local State / Country International International Product Forms Mainly Inhalation, Edible Basic to Advanced Formulations A
Slide 6: RHO Phyto
1.1 RHO Phyto The future of cannabinoid-based medicine Portfolio of proprietary and evidence products 6 © 2025 Avicanna Inc.
Slide 7: Rho Phyto & the Canadian Commercial Platform
1.1.1 Rho Phyto & the Canadian Commercial Platform 38 Proprietary SKUs across various commercial channels National Medical Channels Provincial Retail Channels 38 8 Proprietary National medical commercial SKUs cannabis portals (including MyMedi.ca) 135 11 Commercial listings Manufacturing (medical an
Slide 8: MyMedi.ca: A Complete Medical Cannabis Care Platform
1.2 Established through the acquisition of MyMedi.ca A Complete Medical Cannabis Care Platform “We are grateful for the trust placed in us by our medical cannabis patients over the past few years, and are confident we’ve found the right partner in Avicanna to continue to support them. As we move awa
Slide 9: MyMedi.ca
1.2.1 MyMedi.ca Nationwide Medical Cannabis Pharmacy and Patient Support Program • Medical cannabis portfolio formulary - with 200+ SKUs from over 50 Canadian brands • Pharmacist-led and bilingual patient support programs • Specialty care programs including compassionate pricing and Veterans’ affair
Slide 10: Medical Affairs, Education and Training
1.2.2 Medical Affairs, Education and Training Patients • Education on the potential benefits and risks associated with medical cannabis • Pharmacist led dosing and product support Scope of Care for Patients • Harm reduction education and initiatives Scope of Care for Healthcare Practitioners Simplify
Slide 11: Pharmaceutical Pipeline of Indication Specific Products
1.3 Pharmaceutical Pipeline of Indication Specific Products Developed through the Company’s R&D, clinical and commercial platforms Medical Cannabis Medical Cannabis Pharmaceutical Products Care Platform* Pipeline *MyMedi.ca is operated by Northern Green Canada for the Canadian market 11 © 2025 Avican
Slide 12: Pharmaceutical Pipeline and Drug Candidates
1.3.1 Pharmaceutical Pipeline and Drug Candidates Designed to Address 5 Major Clinical Areas Sleep Eczema/ Pain Anxiety & Epilepsy Epidermolysis Bullosa Management Depression • Candidates are in various stages of R&D, pre-clinical to • Leveraging the company’s scientific platform and vertical real w
Slide 13: Trunerox 10% CBD Oral Solution
1.3.2 TruneroxTM 10% CBD Oral Solution Adjunctive Treatment of Seizures Associated with Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS) • Marketing authorization obtained in Colombia by INVIMA Q1 2024 • Expected commercialization in Colombia 2025 • Proprietary formulation manufactured under G
Slide 14: Osteoarthritic Pain Phase II Pilot (Initiated)
1.3.3 Osteoarthritic Pain Phase II Pilot (Initiated) A UHN led internal Pilot, Placebo Controlled, Blinded Randomized Multicentre Trial • The RCT is led Hance Clarke, MD, FRCPC, PhD as the principal investigator is the medical director of the Pain Research Unit, and a clinician at University Health
Slide 15: Active Pharmaceutical Ingredients (Aureus Santa Marta)
1.4 Active Pharmaceutical Ingredients (Aureus Santa Marta™) 15 © 2025 Avicanna Inc.
Slide 16: Active Pharmaceutical Ingredients (Aureus Santa Marta)
1.4.1 Active Pharmaceutical Ingredients (Aureus Santa Marta™) Avicanna’s Supply Chain Business Segment and Vertical Integration Raw Material Business Unit and Brand • 3 international pharmaceutical marketing authorizations with Aureus API including TruneroxTM • Avicanna’s low cost and consistent sup
Slide 17: Avicanna Around the World
1.5 Avicanna Around the World Global Operations and Exports - 22+ Countries 17 © 2025 Avicanna Inc.
Slide 18: Scientific Platform
2.0 Scientific Platform R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products 18 © 2025 Avicanna Inc.
Slide 19: Established Scientific Platform
2.1 Established Scientific Platform 30+ Proprietary 10+ Scientists Commercial Products Extensive Pharmaceutical IP Portfolio including Pipeline USPTO granted patents 11 Canadian Government Research 100% Ownership of Grants Awarded Since 2020 All IP and Trade Secrets 19 © 2025 Avicanna Inc.
Slide 20: World-Class Institutional Collaborations
2.2 World-Class Institutional Collaborations 20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions Since 2017 20 © 2025 Avicanna Inc.
Slide 21: Financial Overview
3.0 Financial Overview 21 © 2025 Avicanna Inc.
Slide 22: Financial Highlights
2024 Highlights 3.1 Financial Highlights Total Revenue Gross Profit $25.5M $12.9M Q1 2025 (first profitable quarter) 52% Y-Y growth 94% Y-Y increase 51% 68% Net Income Gross Profit Gross Margins Adjusted EBITDA $74,154 $3.54M Improvement Improvement narrowed from 40% in 2023 lost to $1.4M in 2024 Compre
Slide 23: Management and Board of Directors
3.2 Management and Board of Directors Senior Management Team Board of Directors Aras Azadian Aras Azadian Founder and CEO Founder and CEO Phillip Cardella Eileen McCormack Chief Financial Officer Independant Director Stephen Kim John McVicar Chief Legal Officer & General Counsel Independant Director
Slide 24: Timeline and Evolution
3.3 Timeline and Evolution 1 3 5 7 9 11 Launched of RHO Phyto Avicanna Inc. is R&D and pharmaceutical IPO on Toronto Stock into major Canadian Acquisition of First incorporated and collaboration with the Exchange (TSX: AVCN) hospitals, initially with Medical Cannabis by profitable begins operations i
Slide 25: Corporate Highlights
3.4 Corporate Highlights • Scale-up and internalization stage with 4 business pillars • Diversified - scalable and high margin revenue streams focused on intellectual property • Addressing a global market opportunity with medical and pharmaceutical cannabinoid-based products • 30+ commercial SKUs an
Slide 26: Thank You
Thank You TSX: AVCN avicanna.com info@avicanna.com